{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:10:03Z","timestamp":1772165403415,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1745-6215-15-314","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T21:02:04Z","timestamp":1407358924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect"],"prefix":"10.1186","volume":"15","author":[{"given":"Patrick","family":"Royston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh KB","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,7]]},"reference":[{"key":"2189_CR1","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1002\/sim.3623","volume":"28","author":"M Schemper","year":"2009","unstructured":"Schemper M, Wakounig S, Heinze G:The estimation of average hazard ratios by weighted Cox regression. Stat Med. 2009, 28: 2473-2489. 10.1002\/sim.3623.","journal-title":"Stat Med"},{"key":"2189_CR2","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.4274","volume":"30","author":"P Royston","year":"2011","unstructured":"Royston P, Parmar MKB:The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011, 30: 2409-2421. 10.1002\/sim.4274.","journal-title":"Stat Med"},{"key":"2189_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch PM, Therneau TM:Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994, 81: 515-526. 10.1093\/biomet\/81.3.515.","journal-title":"Biometrika"},{"key":"2189_CR4","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/sim.1203","volume":"21","author":"P Royston","year":"2002","unstructured":"Royston P, Parmar MKB:Flexible proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002, 21: 2175-2197. 10.1002\/sim.1203.","journal-title":"Stat Med"},{"key":"2189_CR5","volume-title":"Flexible parametric survival analysis using Stata: beyond the Cox model","author":"P Royston","year":"2011","unstructured":"Royston P, Lambert PC: Flexible parametric survival analysis using Stata: beyond the Cox model. 2011, College Station, Tx: Stata Press"},{"key":"2189_CR6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M:Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med. 2009, 361: 947-957. 10.1056\/NEJMoa0810699.","journal-title":"New Engl J Med"},{"key":"2189_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S1470-2045(12)70567-3","volume":"14","author":"D Stark","year":"2013","unstructured":"Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T:Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013, 14: 236-243. 10.1016\/S1470-2045(12)70567-3.","journal-title":"Lancet Oncol"},{"key":"2189_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10985-004-4771-0","volume":"10","author":"PK Andersen","year":"2005","unstructured":"Andersen PK, Hansen MG, Klein JP:Regression analysis of restricted mean survival time based on pseudo-observations. Lifetime Data Anal. 2005, 10: 335-350.","journal-title":"Lifetime Data Anal"},{"key":"2189_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M:Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med. 1996, 334: 1-6. 10.1056\/NEJM199601043340101.","journal-title":"New Engl J Med"},{"key":"2189_CR10","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa1206300","volume":"368","author":"KS Thomas","year":"2013","unstructured":"Thomas KS, others for the PATCH1 Trial Team:Penicillin to prevent recurrent leg cellulitis. New Engl J Med. 2013, 368: 1695-1703. 10.1056\/NEJMoa1206300.","journal-title":"New Engl J Med"},{"key":"2189_CR11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR:Regression models and life-tables (with discussion). J R Stat Soc (Series B). 1972, 34: 187-220.","journal-title":"J R Stat Soc (Series B)"},{"key":"2189_CR12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1536867X0500500114","volume":"5","author":"FMS Barthel","year":"2005","unstructured":"Barthel FMS, Royston P, Babiker A:A menu-driven facility for complex sample size calculation in randomized controlled trials with a survival or a binary outcome: update. Stat J. 2005, 5: 123-129.","journal-title":"Stat J"},{"key":"2189_CR13","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1002\/sim.2517","volume":"25","author":"FMS Barthel","year":"2006","unstructured":"Barthel FMS, Babiker A, Royston P, Parmar MKB:Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over. Stat Med. 2006, 25: 2521-2542. 10.1002\/sim.2517.","journal-title":"Stat Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-15-314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T20:29:24Z","timestamp":1717187364000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/1745-6215-15-314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,7]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2189"],"URL":"https:\/\/doi.org\/10.1186\/1745-6215-15-314","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718524278.793498628","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,7]]},"assertion":[{"value":"17 September 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"314"}}